Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | PDE6C | P51160 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021599 | 0.88 | ADORA2B (0.43) | ADORA2BADORA2ACFTRCYP1A2PDE2A | |
| SCHEMBL9806961 | 0.87 | ADORA2B (0.36) | ADORA2BADORA2ACFTRCYP1A2PDE2A | |
| SCHEMBL6751928 | 0.85 | ADORA2B (0.35) | ADORA2BADORA2ACFTRCYP1A2PDE2A | |
| SCHEMBL15743132 | 0.80 | ADORA2A (0.33) | ADORA2BADORA2ACYP1A2PDE4APDE4B | |
| SCHEMBL17186266 | 0.77 | PNP (0.42) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17186305 | 0.77 | PNP (0.39) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL441798 | 0.77 | DPP4 (0.44) | ADORA2BADORA2ACYP1A2PNPATAD2 | |
| SCHEMBL20576 | 0.76 | PNP (0.34) | ADORA2BADORA2ACYP1A2PDE4AADORA1 | |
| SCHEMBL20866 | 0.76 | ATAD2 (0.41) | ADORA2BADORA2ACYP1A2PDE4AADORA1 | |
| SCHEMBL473734 | 0.76 | ADORA2A (0.32) | ADORA2BADORA2ACYP1A2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | disclosed |
| US-20200109362-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-09 | — | — | US | disclosed |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DELMAR PHARMACEUTICALS INC (CA) | 2018-05-31 | — | — | US | disclosed |
| US-9901563-B2 | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol | DELMAR PHARMACEUTICALS, INC. (CA) | 2018-02-27 | — | — | US | disclosed |
| WO-2017223254-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | disclosed |
| US-20150297553-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2015-10-22 | — | — | US | disclosed |
| WO-2015120254-A1 | DISULFIRAM COMPOSITIONS AND TREATMENTS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-08-13 | — | — | WO | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8324282-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-26 | — | — | US | disclosed |
| EP-0702683-B8 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003070234-A9 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6635677-B2 | Potentiating toxicity of 1,3-bis(chloroethyl)2-nitrosourea | CASE WESTERN RESERVE UNIVERSITY | 2003-10-21 | — | — | US | disclosed |
| EP-0702683-B1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20020198264-A1 | Methoxyamine combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2002-12-26 | — | — | US | disclosed |
| US-6465448-B1 | TREATING TUMORS RESISTANT TO TEMOZOLOMIDE ALONE | CASE WESTERN RESERVE UNIVERSITY | 2002-10-15 | — | — | US | disclosed |
| WO-2001012199-A2 | METHOXYAMINE POTENTIATION OF TEMOZOLOMIDE ANTI-CANCER ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-0702683-A1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | UNG, TOP2A, OGG1 | ADORA2B 1682/4885ADORA2A 836/4885CFTR 4382/4885 |
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | ADORA2B 2056/4885ADORA2A 792/4885CFTR 3218/4885 |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | MGMT, NNMT, GNMT | ADORA2B 1038/4885ADORA2A 477/4885CFTR 1945/4885 |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DDOST, DAD1, B3GAT3 | ADORA2B 3605/4885ADORA2A 2834/4885CFTR 3422/4885 |
| US-20150297553-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DDOST, DAD1, B3GAT3 | ADORA2B 3605/4885ADORA2A 2834/4885CFTR 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.